Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page * p+ b! e7 f4 n" P' g5 ?
: S5 Z* F: H0 L S( s7 o. j9 s; z6 B6 _4 M* E! h+ K% P! D
Sub-category:9 X! s: m6 p6 U% ]; R7 Q, Y
Molecular Targets + a. H, v) b% {3 n% u0 E
, A( p/ Y) [6 l6 y7 V9 f% H, S* R b, q/ p# ~4 O; Y3 N* j* y& C
Category:3 r% y' h) ]. b+ j( s5 E8 h
Tumor Biology - E; a/ m0 B9 D X1 t- o% Y1 l
" \1 ]3 q) ?5 y9 g
* s9 r! Z3 _# g/ d3 X( _Meeting:' e4 z+ Q. n3 M. h2 [1 S, a
2011 ASCO Annual Meeting ' s, |9 L% j7 R2 P2 O/ D
W0 i T2 b9 p& n# g" y- U5 l: c+ o9 @. f5 l3 v! Q9 U8 _
Session Type and Session Title:' I5 O9 A5 z! s7 ]
Poster Discussion Session, Tumor Biology
% B0 w; K- g7 L2 G& a+ U) H' z9 |8 A
% _# h, b- ?& c+ B E3 q% f8 w- c
Abstract No:7 {; |7 C6 u9 B2 Z5 V
10517
5 z. [9 ~( Z5 R+ d# a' w; O K" A2 {
% x! w, _& `( e: {9 J3 gCitation:
6 A$ G3 S2 j6 y. d3 A. c$ i6 Q2 FJ Clin Oncol 29: 2011 (suppl; abstr 10517)
' N* R* p/ I# w& D; t
: ?; r+ |3 F7 A: P h4 t5 d! P/ M7 Z7 T+ I+ G* W( o
Author(s):
( M* _) l. E! Y: E' W* z7 jJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China - C6 L. a& E. s6 T/ N' _
! ?* C3 B H, S5 K
6 ~: {6 s& D7 d# u8 a3 J9 p; q% P4 V
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
( D" F; |' R- E2 M* O% `% g1 C0 e5 L+ U! {& m
Abstract Disclosures
2 U. |9 }9 N+ T( A' K1 a3 o* Q' k O# g8 j3 {$ X& f
Abstract:
$ b( J8 A# n: Y% u9 F" k+ |/ B" \" K& K: K# ^+ O$ T/ y
+ F! b4 y3 @8 D. v) ~$ x
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
2 T# |& E# k6 ~' ?# \" C7 C( Y5 I
) b& U% L% N' P0 z7 m: B
1 k6 z) z0 p' F' F% ?, ? |
父亲确诊“癌王”生命危在旦夕，医护
讲述者：吉吉整理者：pear
一年前，父亲被确诊为胰腺癌伴肝转移，那一刻，我的人生仿
三代药泰瑞沙五年骨转，请教后续方案
17年右锁骨异常，穿刺确诊肺CA，基因检测19突变，无其他转移。服用易瑞沙，至2019肺部
重磅好消息！这三款肺癌靶向药进医保
12月7日，国家医保局公布最新医保目录，三款肺癌靶向药——氟泽雷塞、他雷替尼、塞普
权威开讲！仲佳教授详解小细胞肺癌治
作者：雨过天晴在肺癌家族中，小细胞肺癌虽仅占15%-20%的比例，却以“恶性程度高、进
林根教授、王秀问教授：肺癌罕见靶点
整理者：雨过天晴审核人：鹰版在精准医疗的推动下，ALK、ROS1等靶点的发现为部分非小
. k0 L( D# `! J% _; i" @% p" V. l" Z
显身卡
